Factor VIII/von Willebrand factor - Octapharma

Drug Profile

Factor VIII/von Willebrand factor - Octapharma

Alternative Names: Human factor VWF/FVIII concentrate; Wilate

Latest Information Update: 04 May 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Octapharma
  • Class Antihaemorrhagics; Blood coagulation factors; Coagulants; Recombinant proteins
  • Mechanism of Action Blood coagulation factor replacements; Factor X stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Von Willebrand disease
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Haemophilia A; Von Willebrand disease

Most Recent Events

  • 29 Mar 2018 Octapharma completes a phase III trial in Haemophilia A (In adolescents, In adults) in Bulgaria, Hungary, Poland, Romania and Russia (NCT02954575, EudraCT2016-003681-34)
  • 22 Nov 2017 Phase-III clinical trials in Haemophilia A (In infants, In children) in Ukraine (IV) (NCT03376516)
  • 22 Nov 2017 Octapharma initiates a phase III trial in Haemophilia A (In infants, In children) in Russia (NCT03376516)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top